Purpose of review
Recent data support postoperative radiotherapy in the management of selected patients with localized prostate cancer; however, optimal patient selection and timing of additional treatment are uncertain. Data describing selection factors for treatment and literature supporting immediate or delayed radiotherapy are reviewed and the limitations of current knowledge are discussed. Recent findings Three randomized controlled trials showed an advantage of combined surgeryradiotherapy when compared with surgery alone for biochemical relapse-free survival, local control and, in one trial, overall survival for those with pT3 disease and/or positive surgical margin. These trials only compared early postoperative radiotherapy with no radiotherapy. Toxicity of combined therapy is worse than that of surgery alone, so a preferable strategy might be to limit treatment to those who demonstrate postoperative biochemical progression. Only retrospective evidence exists to support this approach. Summary Optimal timing and selection of patients for postoperative radiotherapy will only be determined from the results of important randomized controlled trials such as Medical Research Council/National Cancer Institute of Canada Clinical Trials Group Radiotherapy and Androgen Deprivation In Combination After Local Surgery (RADICALS), and these should be strongly supported. In the absence of new data, immediate postoperative radiotherapy for men with adverse pathology should be the standard of care, and these men should be referred to a radiation oncologist soon after surgery to discuss the relative merits of immediate or delayed postoperative therapy or entry into a clinical trial. This review will address the known benefits and limitation of combined surgery and radiation therapy for prostate cancer and highlight the ongoing controversies and the steps being taken to address them.
Predictors of failure following radical prostatectomy
The probability of complete surgical excision following radical prostatectomy will be determined by patient selection and thoroughness of the preoperative assessment [2,3] and, possibly, by the surgical technique [4-6]. The contemporary literature reports surgical margin positivity rates of 11-38% in those undergoing radical prostatectomy [7] , although this may increase if the trend continues toward operating on patients with higher risk and more locally advanced disease [8] [9] [10] .
Despite the value of pretreatment nomograms for predicting outcome following radiotherapy for clinically localized disease [11] , radical prostatectomy provides additional prognostic information that may be used to better individualize postoperative therapy [12] . This includes establishing the pathological T and N classification, a more representative Gleason score [13] and tumor volume [14] and the surgical margin status. Postoperative PSA kinetics may also provide an early indicator of surgical outcome, as complete resection of the prostate and tumor should be associated with an undetectable postoperative PSA.
The clinical significance of a rising postoperative PSA was described by Pound et al.
[1] in their classical report of 304 men followed for a rising PSA without treatment for a median 5.3 years after radical prostatectomy. Metastatic disease developed in 34% at a median time of 8 years from the time of the PSA elevation. The time to postoperative PSA recurrence was also a significant predictor of metastases-free survival on univariate analysis. Subsequent reports have confirmed the adverse clinical significance of biochemical failure following radical prostatectomy [15] , as well as the adverse prognostic significance of a rapid PSA doubling time (PSADT) [16] . A recent report using ultrasensitive PSA assays has shown postoperative PSA levels above 0.1 ng/ml to be clinically significant [17] .
The clinical significance of postoperative pathologic findings and identification of a positive surgical margin (PSM) has been reported in large series by a number of investigators. Swindle et al. [18] reported the Memorial Sloan-Kettering Cancer Center (MSKCC) experience of 1389 men undergoing radical prostatectomy with a median follow-up of 50 months. Adjuvant radiotherapy was used in only 29 of 179 with PSM. The 5-year PSA progressionfree probability was 65.6 vs. 84.9% for those with positive and negative surgical margin, respectively. Ten-year predictors of PSA progression-free probability on multivariable analysis were surgical margin status, extracapsular extension, seminal vesicle invasion, Gleason score and lymph node involvement. Resnick et al. [19] reported on 429 men with a PSM who achieved an undetectable PSA nadir postoperatively. At a median 60-month followup, the significant predictors of biochemical progression included tumor volume of more than 2 cm 3 and the presence of multiple PSM. The location of PSM was not significant.
Boorjian et al. [12] reviewed 11 729 men who underwent radical prostatectomy during 1990-2006, with a median follow-up of 8.2 years. The PSM rate was 31.1%. The 10year biochemical progression-free rate was significantly different at 77 vs. 56% for negative and positive surgical margin, respectively, as was the clinical local recurrencefree survival of 95 vs. 89%. Multivariate analysis showed that a PSM was associated with increased risk of biochemical recurrence, local recurrence and receipt of salvage therapy. It did not predict for systemic progression, cancer-specific death or overall mortality, although this may reflect the routine use of salvage therapy in this cohort.
The Southwest Oncology Group (SWOG) 8794 trial [20] was a randomized comparison of surgery alone vs. surgery plus postoperative radiotherapy for men with pT3 disease. This trial has the advantage of long followup and a 10-year failure analysis [21] , and this has reported clinical local failure for the surgery alone cohort in 20% of those with a postsurgical PSA of less than 0.2 ng/ml, 25% of those with a postsurgical PSA 0.2-1.0 ng/ml and 28% of those with a postsurgical PSA of more than 1.0 ng/ml. These reports confirm the adverse prognostic significance of pT3 disease and demonstrate the significance of a persistent or rising postoperative PSA and the presence of a PSM for predicting both local and distant clinical failure. These findings support the need for effective postoperative therapy for these patients.
The role of postoperative radiotherapy in prostate cancer
The efficacy of radiotherapy as a primary modality for prostate cancer would also suggest a role for postoperative radiotherapy to convert a noncurative situation into a curative one through sterilization of residual microscopic cancer in the prostate bed. However, the efficacy of this approach requires that residual disease be confined to a definable treatment volume in or near the prostate bed, and that individuals with strictly localized disease are properly identified before treatment. It also assumes that radiotherapy can be given safely in the postoperative setting.
There are two basic approaches to integrate postoperative radiotherapy into the treatment of prostate cancer. One is to offer postoperative radiotherapy soon after surgery to all considered at high risk of relapse, based on adverse pathological findings such as pT3 disease or PSM, irrespective of the postoperative PSA reading. The other is to delay treatment until there is clear biochemical evidence of progression. The advantage of the first approach is to provide treatment when tumor burden is lowest, although some will receive unnecessary treatment as a consequence. The advantage of the second approach is to limit treatment to those who demonstrate a need through biochemical progression; however, tumor burden will be greater at the time of treatment and there is a risk of metastatic progression during the observation interval. It is also apparent that these options and any related research rely on a definition of PSA remission and progression that changes as PSA testing becomes more sensitive.
All three published randomized controlled trials (RCTs) of postoperative prostate radiotherapy have compared immediate postoperative radiotherapy with no additional treatment for high-risk individuals, and two were conducted before the era of sensitive PSA testing. All data relating to delayed postoperative treatment of prostate cancer come from single institutional or multiinstitutional retrospective series, and the two approaches to postoperative radiotherapy have not been directly compared.
Immediate postoperative radiotherapy
The three RCTs investigated the role of immediate postoprative radiotherapy for high-risk individuals [20,22 ,23 ] . The previously cited SWOG 8794 trial [20] was a randomized comparison of surgery plus observation vs. surgery plus postoperative radiotherapy (60-64 Gy) for 431 men with pT3N0 disease. A positive margin or undetectable postoperative PSA was not required for entry. A recent update [24 ] presented median 12.5-year follow-up data. Salvage radiotherapy was given according to physician preference to 32% of the observation patients at a median of 2 years after randomization, and despite the potential dilution effect of salvage therapy, immediate radiotherapy was associated with significantly improved 10-year metastases-free survival (71 vs. 61%) and overall survival (77 vs. 64%).
Bolla et al. [22 ] reported early 5-year results of European Organization for Research and Treatment of Cancer (EORTC) 22911, which included 1005 men with pT3 or pT2 PSM, N0 disease randomized to immediate post-operative radiotherapy (60 Gy) vs. wait and see. A detectable PSA was identified in 30% of patients postoperatively, and salvage radiotherapy was given according to physician preference to 23% of those on observation. Significant advantage to immediate radiotherapy was seen for 5-year biochemical progression-free survival (74 vs. 53%) and clinical local control (94.1 vs. 84.6%). Longer follow-up will determine whether this early biochemical and clinical advantage to postoperative radiotherapy translates into a survival advantage for these patients.
Van der Kwast et al. [25] performed central pathology review on 552 of these patients. They demonstrated that margin status was the strongest predictor of prolonged biochemical disease-free survival with immediate postoperative radiotherapy, and treatment prevented 291 events/1000 for those with positive margins vs. 88 events/1000 for those with negative margins. Margin location was not predictive of outcome.
Wiegel et al. [23 ] reported on 385 men with pT3N0 tumors randomized to immediate postoperative radiotherapy (60 Gy) compared with wait and see. Those with a persistently detectable postoperative PSA received immediate postoperative treatment irrespective of the random treatment assignment and another 39 did not receive the randomly assigned therapy. An intention-totreat analysis showed improved 5-year biochemical progression-free survival for those randomized to receive postoperative radiotherapy (55 vs. 44%) that did not quite reach statistical significance (P ¼ 0.054). A second intention-to-treat analysis of the subgroup of 307 patients randomized with an undetectable postoperative PSA showed a statistically significant advantage in 5-year biochemical progression-free survival for immediate postoperative radiotherapy (72 vs. 54%). This trial suffers from short follow-up and serious methodology flaws; however, the results do not contradict the findings of the two earlier and larger trials.
Salvage postoperative radiotherapy
Salvage postoperative radiotherapy (SRT) for biochemical or clinical local failure has only been investigated retrospectively in single centre studies or multi-institutional pooled series. These reports span decades and interpretation is cofounded by variability in patient selection, radiation techniques and usage of hormone therapy, follow-up intervals and definition of biochemical failure.
In the more recent literature, long-term biochemical relapse-free survival (bFRS) associated with SRT is 6-year actuarial 32-57% [26, 27] , 7-year actuarial 51.9% [28] , 8-year actuarial 35% [29] and 10-year actuarial 25% [30] . These wide ranges reflect follow-up duration and patient selection factors used, and a variety of predictive factors have been proposed for SRT.
Indicators of tumor burden at the time of radiotherapy include presence of palpable disease or PSA level at the time of radiotherapy. Pathological and biochemical indicators of potential local or systemic disease include PSM, seminal vesicle involvement, lymphovascular invasion, nodal involvement, Gleason score, postoperative PSA doubling time and biochemical response to radiotherapy.
The presence of palpable local disease has been identified by several authors as a poor prognostic indicator with biochemical control rates of 0-11% [31, 32] . MacDonald et al. [33] reported a significantly worse 5-year survival rate (78 vs. 96%) for those treated for clinical relapse.
Prognostic factors in large series predictive of biochemical control on univariate analysis include Tcategory, race/ethnicity, pT3 disease, seminal vesicle involvement, Gleason score and preradiotherapy PSA level [34, 35] . Only low preradiotherapy PSA [34, 35] or Gleason score [35] remained independently predictive of PSA failure on multivariate analysis.
Stevenson et al. [36] reported a pooled series of 1540 patients treated with salvage radiotherapy from 17 North American institutions. The overall 6-year actuarial bRFS was 32%. Detailed analysis of 1326 patients who did not receive hormone therapy demonstrated a 4-year bRFS of 69% for the most favorable prognostic group (preradiotherapy <2.0, Gleason score <8, PSM and postprostatectomy PSADT >10 months). The 4-year bRFS for the least favorable group was 18% (preradiotherapy >2.0, Gleason score >7, PSM negative). For the entire cohort, multivariable Cox regression analysis demonstrated the following prognostic factors to be significant for bFRS following SRT: PSA level before SRT, prostatectomy Gleason score, PSADT, surgical margin status, androgen deprivation therapy before or during SRT and lymph node metastases.
Toxicity of combined surgery and radiotherapy
The toxicity profiles of surgery and external beam radiotherapy for localized prostate cancer differ. The most frequent side-effects of surgery include erectile dysfunction, urinary incontinence and urethral stricture [37] [38] [39] . The most frequent permanent side-effects of radiotherapy include erectile dysfunction and urinary and rectal frequency, urgency and bleeding. Also, late or permanent radiation-related toxicity evolves slowly, with about 80% of effects apparent by 3 years following treatment [40] [41] [42] [43] . Unsurprisingly, evidence supports that the toxicity of combined treatment is worse than that of either treatment alone [20, 22, 44] .
Treatment-related complications were reported in two RCTs that evaluated combined surgery-radiotherapy for localized prostate cancer. Bolla et al. [22] reported significantly higher cumulative 5-year incidence of grade 2 or 3 late Radiation Therapy Oncology Group's late effects of normal tissue toxicity in the combined treatment arm. The most severe late toxicity seen (grade 3) was 4.2% in the combined group and not significantly worse than that of the surgery alone group (2.6%). An interim analysis failed to demonstrate increased urinary incontinence with combined therapy [45] . Thompson et al. [20] reported complications in their trial after a much longer follow-up of 10.6 years. Adverse events were significantly more common in those treated with combined therapy, including rectal complications (3.3 vs. 0%), and urethral stricture (17.8 vs. 9.5%). As with Bolla et al., total urinary incontinence was not significantly worse in the combined treatment group (6.5 vs. 2.8% for surgery alone).
Feng et al. [46] reported late effects in a pooled retrospective analysis of 959 men treated with surgery and radiotherapy. Late genitourinary toxicity was seen in 10% (grade 2) and 1% (grade 3) at 5 years. The late gastrointestinal toxicity was 4% (grade 2) and 0.4% (grade 3) at 5 years.
Erectile dysfunction was not addressed in any of these reports, although the impact of combined surgery and radiotherapy on health-related quality of life has been reported in a limited fashion by others.
Moinpour et al. [47] provide the only randomized data on health-related quality of life from the previously cited SWOG trial. Patients who received radiotherapy reported statistically significantly worse bowel function through year 2 and worse urinary function throughout the course of the study than those treated with surgery alone. After the acute treatment period, urinary function remained stable over time; however, rectal function deteriorated over time for those in both treatment groups. Erectile dysfunction was almost universally present at the time of randomization and did not change between treatment groups over time. At 5 years, improvement to 80% dysfunction was seen in both groups. Global health-related quality of life was worse during radiotherapy (40% normal vs. 56% normal), although this was reversed by year 5 when 69% treated with radiotherapy reported normal global functioning vs. 51% for the surgery alone group.
These reports indicate that although there is increased toxicity in the bowel, bladder and sexual domains associated with the additional postoperative radiotherapy, the overall impact on function and quality of life is not great, and this should not be a deterrent to therapy.
Additional work is required to modify radiation treatment techniques [48] to reduce the toxicity of combined therapy and to mitigate the effects.
Adjuvant or early salvage radiotherapy?
The preceding discussion shows that the available level 1 evidence supports the use of immediate postoperative radiotherapy for those with adverse pathologic features, and that radiotherapy in this setting will improve biochemical control, clinical local control and, in one trial, overall survival.
However, these trials were designed to compare immediate postoperative radiotherapy with no radiotherapy and were conducted before the era of sensitive PSA testing. Patients who were randomized into these studies would be considered candidates for adjuvant and salvage radiotherapy today. Furthermore, these trials demonstrated that not every man who received postoperative radiotherapy was cured and not every observed man progressed. It is clear that the addition of postoperative radiotherapy will modestly increase the rate of long-term genitourinary, gastrointestinal and sexual side-effects.
Further information is required to best determine who is most likely to benefit postoperatively from observation or immediate postoperative radiotherapy or, possibly, even a more aggressive approach with combined adjuvant local and systemic therapy. These data will only come from the results of ongoing randomized trials such as the MRC/ NCIC-CTG RADICALS, and it is crucial that trials such as these are supported.
In the absence of these data, it is important that patients with adverse postoperative findings such as pT3 and PSMs are given the opportunity to discuss the merits and limitations of immediate postoperative radiotherapy with a radiation oncologist. It is also important that oncologists and patients who are considering observation with early salvage radiotherapy in the postoperative setting recognize that there is no level 1 evidence to support this approach, and that the available literature consistently shows a continuously positive association between good outcomes and lower PSA levels at treatment.
Conclusion
Overall, the majority of patients who receive salvage radiotherapy progress despite treatment. Although this would suggest that adjuvant systemic therapy might be beneficial, there is no evidence to guide the use of systemic therapy for these men and no consistent approach to using it. Systemic adjuvant regimens need to be tested in randomized trials, and in the absence of data, treatment guidelines for the use of adjuvant hormone therapy need to be established.
Finally, the concept of postoperative radiotherapy will become more acceptable if radiotherapy-related toxicity can be mitigated, and work is underway to optimize the postoperative radiotherapy treatment volume, dose and treatment techniques [48, 49] .
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